NeuroDerm has completed 3 Phase II studies that have established a robust platform of evidence supporting the safety, tolerability, and preliminary efficacy of ND0612 in people with Parkinson’s disease experiencing motor fluctuations.
ND0612 clinical trials current status:
Phase 2Let's Stay in Touch
For general inquiries or to learn more about NeuroDerm, please complete the form below. For medical information or to report on your own health or experience, please consult your healthcare provider. Please click here for information about our clinical trials.
